Enanta Pharmaceuticals Inc (ENTA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Enanta Pharmaceuticals Inc (ENTA) has a cash flow conversion efficiency ratio of -0.061x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.16 Million) by net assets ($116.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Enanta Pharmaceuticals Inc's balance sheet to measure how much of total assets are equity-financed.
Enanta Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Enanta Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ENTA cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Enanta Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Enanta Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Plumas Bancorp
NASDAQ:PLBC
|
0.021x |
|
Ve Wong Corp
TW:1203
|
0.048x |
|
Royal Group Co Ltd
SHE:002329
|
0.068x |
|
STL Technology Co Ltd
TWO:4931
|
0.090x |
|
ATN International Inc
NASDAQ:ATNI
|
0.047x |
|
Visco Vision Inc.
TW:6782
|
0.061x |
|
Shanghai Trendzone Decor Grp
SHG:603030
|
0.052x |
|
Beijing InHand Networks Technology Co Ltd
SHG:688080
|
0.071x |
Annual Cash Flow Conversion Efficiency for Enanta Pharmaceuticals Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Enanta Pharmaceuticals Inc from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see ENTA market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $64.72 Million | $-19.27 Million | -0.298x | +51.30% |
| 2024-09-30 | $128.81 Million | $-78.76 Million | -0.611x | -28.47% |
| 2023-09-30 | $216.74 Million | $-103.15 Million | -0.476x | -80.39% |
| 2022-09-30 | $321.33 Million | $-84.78 Million | -0.264x | -50.56% |
| 2021-09-30 | $399.43 Million | $-70.00 Million | -0.175x | -1226.35% |
| 2020-09-30 | $455.58 Million | $7.09 Million | 0.016x | -89.92% |
| 2019-09-30 | $462.49 Million | $71.42 Million | 0.154x | +108.05% |
| 2018-09-30 | $393.68 Million | $29.22 Million | 0.074x | -57.47% |
| 2017-09-30 | $301.68 Million | $52.65 Million | 0.175x | +31.57% |
| 2016-09-30 | $269.94 Million | $35.81 Million | 0.133x | -59.14% |
| 2015-09-30 | $236.16 Million | $76.67 Million | 0.325x | +139.18% |
| 2014-09-30 | $148.65 Million | $20.18 Million | 0.136x | +40.76% |
| 2013-09-30 | $110.47 Million | $10.65 Million | 0.096x | -81.27% |
| 2012-09-30 | $43.93 Million | $22.62 Million | 0.515x | +382.94% |
| 2011-09-30 | $-131.96 Million | $24.02 Million | -0.182x | -- |
About Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respirato… Read more